FMP
NASDAQ
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
2.54 USD
0.14 (5.51%)
Valuation Date:
May 2, 2024 4:00 PM
Share Price on Valuation Date
$2.54
Stock Beta
-0.238
Shares Outstanding
29770374